Federal Xarelto Litigation Preps for June 11th Science Day

Published on May 27, 2015 by Sandy Liebhard

Text-Size:A A A+


Parties involved in the federal litigation established for Xarelto lawsuits in the U.S. District Court, Eastern District of Louisiana, have been directed to prepare presentations for the proceeding’s upcoming Science Day. Scheduled to be held on June 11th, Science Day will provide plaintiffs and the defendants an opportunity to apprise the Court of the scientific and medical issues that may prove relevant to the cases pending in the proceeding.

Xarelto Science Day Format

According to a Pretrial Order issued by the Court on May 21st, topics to be addressed during Science Day include:

  • A background on atrial fibrillation
  • A background on coagulation and anticoagulation therapy
  • Anti-coagulation therapy before the Novel Oral Anti-Coagulants
  • The approved indications and mechanism of action of Xarelto
  • Clinical practice with Xarelto
  • Adverse events with Xarelto
  • Clinical trials pertaining to Xarelto
  • The use of blood test based dosing with Xarelto
  • Xarelto pharmacology

The parties are to provide the Court with a copy of their presentations by June 5, 2015. The presentations must be made by physicians and scientists, who will be questioned by the Court as it deems appropriate. However, none of the experts will be questioned by opposing counsel. Each side will have roughly 1 hour and 45 minutes to make their presentations.

All of the Xarelto presentations will be off the record, and will not be considered admissible for any purpose in the litigation.

Xarelto Litigation Includes More Than 400 Claims

The federal multidistrict litigation underway in Louisiana now includes more than 430 Xarelto lawsuits, all of which were filed on behalf of individuals who allegedly suffered serious episodes of internal bleeding, strokes, deep vein thrombosis, pulmonary embolism, and other dangerous complications related to its use. Plaintiffs claim that marketing materials that positioned Xarelto as a superior alternative to warfarin were misleading, as bleeding tied to that older medication can be stopped via the administration of vitamin K. There is no approved antidote to reverse Xarelto bleeding.

If you or a loved one were hurt by Xarelto, please contact Bernstein Liebhard LLP today to learn more about your legal rights. Our Xarelto attorneys are already representing plaintiffs in this litigation, and they can determine whether or not you might have a valid claim. Please call our office at for your free case review.

Web Analytics